Literature DB >> 3716893

Diagnostic criteria in pituitary tumour recurrence--combined modality of surgery and radiotherapy.

F Rauhut, H E Clar, M Bamberg, G Benker, W Grote.   

Abstract

The tumour recurrence rate of 210 patients with operated hypophysomas were investigated. Depending on the surgical approach, total or subtotal extirpation of the adenomas, the recurrence rates varied from 10,4 to 35%. 33 patients with pituitary tumour recurrences were followed up over a period of 20 years. Clinical symptoms CT-results at relapse are represented. Serum prolactin level (PRL) was determined before and after surgical and radiotherapy of PRL-producing adenomas. In these cases PRL can be accepted as a tumour marker. 13 patients with relapsed hypophysomas received local irradiation (5.7 MeV linear accelerator) after recurrence operation. An individual comparison in the same patient between surgical therapy alone and combined surgical and radiotherapy was possible. Based on the obtained experience with this combined treatment a therapy scheme using combined surgery and radiotherapy in pituitary tumours is suggested.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3716893     DOI: 10.1007/bf01812277

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  16 in total

1.  Pituitary adenoma: results of combined surgical and radiotherapeutic treatment of 260 patients.

Authors:  S G Elkington; W McKissock
Journal:  Br Med J       Date:  1967-02-04

2.  Prolactinoma: a question of rational treatment.

Authors:  C R Edwards; C M Feek
Journal:  Br Med J (Clin Res Ed)       Date:  1981-12-12

Review 3.  Pituitary prolactinomas.

Authors:  J D Nabarro
Journal:  Clin Endocrinol (Oxf)       Date:  1982-08       Impact factor: 3.478

4.  [Drug therapy of hyperprolactinemia and acromegaly].

Authors:  J J Staub; B Althaus; U Wiggli; O Gratzl
Journal:  Schweiz Med Wochenschr       Date:  1983-05-21

5.  Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas.

Authors:  T Eversmann; R Fahlbusch; H K Rjosk; K von Werder
Journal:  Acta Endocrinol (Copenh)       Date:  1979-11

6.  Prolactin-secreting pituitary adenoma. Observations in irradiated patients.

Authors:  A De Schryver; D VandeKerckhove; G Debruyne
Journal:  Acta Radiol Oncol       Date:  1980

7.  Pituitary function in prolactinoma. Effect of surgery and postoperative bromocriptine therapy.

Authors:  R Pelkonen; B Grahne; E Hirvonen; S L Karonen; J Salmi; M Tikkanen; S Valtonen
Journal:  Clin Endocrinol (Oxf)       Date:  1981-04       Impact factor: 3.478

8.  Prolactinomas: surgical therapy, indications and results.

Authors:  S E Rawe; H O Williamson; J H Levine; S A Phansey; D Hungerford; W Y Adkins
Journal:  Surg Neurol       Date:  1980-09

9.  Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma.

Authors:  O Serri; E Rasio; H Beauregard; J Hardy; M Somma
Journal:  N Engl J Med       Date:  1983-08-04       Impact factor: 91.245

10.  Pregnancy following transsphenoidal resection of prolactin-secreting pituitary tumors.

Authors:  E R Laws; N C Fode; R V Randall; C F Abboud; C B Coulam
Journal:  J Neurosurg       Date:  1983-05       Impact factor: 5.115

View more
  3 in total

Review 1.  Intracranial dissemination of pituitary adenoma. Case report and review of the literature.

Authors:  M T Giordana; P Cavalla; A Allegranza; B Pollo
Journal:  Ital J Neurol Sci       Date:  1994-05

2.  Nuclear accumulation of basic fibroblast growth factor as a predictor for the recurrence of pituitary adenomas.

Authors:  Shinji Fukui; Naoki Otani; Hiroshi Nawashiro; Akiko Yano; Takahito Miyazawa; Akira Ohnuki; Nobusuke Tsuzuki; Hiroshi Katoh; Shoichiro Ishihara; Takamoto Suzuki; Katsuji Shima
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

3.  Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence.

Authors:  Atsuo Yoshino; Yoichi Katayama; Takao Fukushima; Takao Watanabe; Chiaki Komine; Takakazu Yokoyama; Kaoru Kusama; Itaru Moro
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.